摘要
介 绍:第一个人类腺相关病毒(AAV)最初是作为腺病毒储备的一种污染物在1960年被发现的,因此它没有医药利益。在过去的30年里,AAV在基因治疗中被广泛使用,主要是由于它的复制缺陷和人类的致病性缺乏。此外,它还能在具有特异性组织嗜性的非分裂和分裂细胞中协调稳定和长期的表达,使AAV成为治疗基因转移的最有希望的候选者之一,用于治疗许多遗传和非遗传性疾病。此外,AAV的使用不仅局限于对重组基因的过度表达,而且还能对短发夹状RNA和microRNA进行过度表达,以降低目标组织中基因的表达。 讨论与结果:本综述分为四部分。在综述的第一部分,我们讨论了AAV的发现和历史,其次是详细的AAV生物学,如病毒基因组、病毒结构及其生命周期。在综述的第二部分,讨论的重点是AAV和组织转导的分子机制,包括受体识别和细胞结合,胞内进入,病毒脱壳,入核和基因组复制。还讨论了利用AAV作为基因传递的安全载体的优势和局限性。在综述的第三部分,我们讨论了人类和非人类灵长类动物中最常用的一种选择性血清型和变种,重点是它们不同的组织形式、转导效率、免疫学特征以及它们在动物研究中的应用。综述的最后一部分重点介绍了近年来的体内基因转移的进展,在临床前和临床背景下使用AAV来治疗遗传和非遗传性疾病,特别强调AAV在肝脏疾病领域的潜在临床应用。
关键词: 腺-相关病毒,血管紧张素转化酶2,基因治疗,肝,非遗传性疾病,肾素血管紧张素系统,病毒载体
Current Gene Therapy
Title:The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders
Volume: 17 Issue: 1
关键词: 腺-相关病毒,血管紧张素转化酶2,基因治疗,肝,非遗传性疾病,肾素血管紧张素系统,病毒载体
摘要: Introduction: The first human adeno-associated virus (AAV) was originally discovered in 1960s as a contaminant of adenovirus stock preparation and thus it had not been of medical interest. Throughout the last three decades AAV has gained popularity to be used in gene therapy, mainly due to its replicative defectiveness and lack of pathogenicity in human. In addition, its ability to mediate stable and long-term expression in both non-dividing and dividing cells with specific tissue tropism makes AAV one of the most promising candidates for therapeutic gene transfer to treat many inherited as well as non-inherited disorders. Moreover, the use of AAV is not only restricted to overexpression of recombinant transgene, but also to over-express short hairpin RNA and microRNA to knockdown the expression of genes in targeted tissues.
Discussion and Conclusion: This review is organized into four parts. In the first part of the review, we discuss about the discovery and history of AAV, followed by detailed AAV biology such as virus genome, virus structure and its life cycle. In the second part of the review, the discussion is centred on the molecular mechanisms of AAV and tissue transduction, including receptor recognition and cell binding, endosomal entry, virus uncoating, nuclear entry and genome replication. Advantages and limitations of using AAV as a safe vehicle for gene delivery is also discussed. In the third part of the review, we discuss about the most commonly used AAV serotypes and variants isolated from human and non-human primates, focusing on their diverse tissue tropisms, transduction efficiency, immunological profiles and their applications in animal studies. Final part of the review focuses on the recent progress of in-vivo gene transfer using AAV for inherited and non-inherited diseases in both preclinical and clinical settings with a special emphasis on potential clinical applications of AAV in the field of liver disease.Export Options
About this article
Cite this article as:
The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders, Current Gene Therapy 2017; 17 (1) . https://dx.doi.org/10.2174/1566523217666170314141931
DOI https://dx.doi.org/10.2174/1566523217666170314141931 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements